The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,730.00
Bid: 1,729.50
Ask: 1,730.50
Change: 1.50 (0.09%)
Spread: 1.00 (0.058%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: SABMiller Accepts Improved AB InBev Offer

Tue, 13th Oct 2015 09:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.
----------
FTSE 100 - WINNERS
----------
SABMiller, up 9.0% at 3,946.50 pence. The Anglo-South African brewing giant has reached a deal to be acquired by larger rival Anheuser-Busch InBev, which increased its offer to GBP44 per share from GBP43.50 on day previously. A formal offer at that price would value SABMiller at GBP71.28 billion, with the combination of the two companies to create a global beer giant with a roughly GBP280 billion market cap. AB InBev now has until 1700 BST on October 28 to decide whether to make an firm offer or walk away.

GlaxoSmithKline, up 1.0% at 1,318.50 pence. JPMorgan upgraded the pharmaceutical company to Neutral from Underweight, and raised its price target to 1,370 pence from 1,320p.
----------
FTSE 100 - LOSERS
----------
Royal Mail, down 4.3% at 451.90 pence. The UK government said it has sold the majority of its 14% stake in Royal Mail PLC for around GBP591.0 million under an accelerated bookbuilding process announced the previous day. The government sold a 13% stake in Royal Mail, comprising around 130.0 million shares, at a placing price of 455.0 pence per share. The remaining 1% stake, equivalent to about 10.0 million shares, will be "gifted" to Royal Mail employees in the UK, marking the government's final disposal of shares.

Barclays, down 2.9%. The lender reportedly plans to name JPMorgan investment banker Jes Staley as its new chief executive, with confirmation to come in the next two weeks depending on regulatory approval. Such a move would put a high profile investment banker in charge at a time when there are big questions about the role of Barclays' investment banking division. Under the ousted Antony Jenkins, a retail banker, Barclays had set about reducing its overall reliance on the division as a source of earnings.

Glencore, down 5.4%. The commodities trader and mining company was down due to concerns about China's economy health. Anglo American, another miner, was down 3.3% and BHP Billiton down 2.0%. China's exports declined at a moderate pace in September as the devaluation of yuan helped it from falling sharply amid weak global demand. At the same time, imports plunged due to a drop in commodity prices and subdued domestic demand.
----------
FTSE 250 - WINNERS
----------
Bellway, up 3.5%. The housebuilder said it should be able to grow volumes by up to 10% in its current financial year, as it reported a 44% jump in pretax profit to GBP354.2 million in the year ended July 31 and raised its dividend to 77.0 pence from 52.0p.

Michael Page International, up 2.1%. The recruitment consultancy said Non-Executive Chairman Robin Buchanan plans to step down, as it reiterated its expectations for its full year. The company said its gross profit in the third quarter of 2015 rose 4.8% to GBP139.2 million from GBP132.9 million in the previous year. This growth was hit by volatility in foreign exchange rates, and at constant currency gross profit would have risen 10.2%.

Sophos Group, up 3.3% at 232.00 pence. Liberum initiated coverage of the security software and hardware developer at Buy with a 290p price target, saying the company has attractive cash dynamics and expects its earnings before interest, taxes, depreciation and amortisation to more than double over the next five years.
----------
FTSE 250 - LOSERS
----------
Weir Group, down 3.7% at 1,298.00 pence. The engineering company was hit by broker price-target cuts. Morgan Stanley cut its price target on Weir Group to 1,200 pence from 1,360p, and reiterated its Underweight rating. Meanwhile, UBS cut its price target on the company to 1,800p from 2,000p, and reiterated a Buy rating.
----------
MAIN MARKET AND AIM - WINNERS
----------
Flybe Group, up 6.6%. The airline on Tuesday boasted double-digit increases in seat capacity, passenger numbers and revenue in its second quarter, but reported a slight decline in passenger load factor.

Mediazest, up 34%. The audio-visual products company said it has secured new business worth a cumulative GBP1.0 million since announcing full-year results in August. It also had won new clients including Diesel SpA, Molson Coors Brewing Co and the John Lewis Partnership, and signed new business with existing clients, such as Hyundai Motor Co, Adidas AG and the Post Office Ltd.

RWS Holdings, up 18%. The patent translation and search company said it enjoyed a "significant" recovery in the second half of its last financial year, a boost after the flat sales performance in the opening six months of the year. The 2% increase in full-year sales, which reached GBP95.1 million, means the numbers were ahead of market expectations prior to the announcement.
----------
MAIN MARKET AND AIM - LOSERS
----------

Arrow Global, down 9.4% at 246.25 pence. Chief Executive Tom Drury, Chief Financial Officer Robert Memmott and other executives, together with an unnamed institutional investor, sold GBP27.5 million of shares in the debt manager. The 11 million shares were sold at 250 pence apiece overnight Monday to Tuesday. They represent a combined stake of 6.3%.

Galantas Gold Corp, down 14%. The company said that an individual intends to challenge its application for planning permission to allow the company to mine underneath the open pit at the Cavanacaw mine in Northern Ireland.

Auhua Clean Energy, down 14%. Chairman David Sumner has resigned due to "increasing demands on his time from his other business commitments", the company said. Raphael Tham has assumed the role of non-executive chairman. Tham was previously vice-chairman.
----------

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.